Abstract
Primary intraocular lymphoma (PIOL) is a rare form of lymphoma which is encountered in ocular oncology practice. Most preferred treatment has been intravitreal MTX injections which do not have a long lasting chemotherapeutic effect due to rapid elimination of the drug. In this study, chitosan (CS) and polylactic acid (PLA) based intraocular implants are fabricated for different MTX loadings (10%, 25% and 40% w/w). The implants administer a therapeutic dosage of 0.2–2.0 μg/day of MTX over a period of a month. PLA coated CS-MTX implants can be used for sustained release of MTX, thereby improving the treatment of PIOL.